Phagelux Overview
- Year Founded
-
2014

- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
8
Phagelux General Information
Description
Developer of bacteriophages designed to provide alternatives to antibiotics for multiple fields. The company offers anti-bacterial products across multiple fields utilizing various phage and phage-based technologies, enabling medical users to solve the bacterial problem and provide treatments to various diseases.
Contact Information
Website
www.phagelux.comCorporate Office
- Room 309, No. 88, Meiliang Road, Mashan Street
- Binhu District
- Wuxi, Jiangsu 214026
- China
Corporate Office
- Room 309, No. 88, Meiliang Road, Mashan Street
- Binhu District
- Wuxi, Jiangsu 214026
- China
Phagelux Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Later Stage VC | 03-Apr-2025 | Completed | Generating Revenue | |||
6. Later Stage VC | 28-Jun-2024 | Completed | Generating Revenue | |||
5. Later Stage VC | 14-Nov-2022 | Completed | Generating Revenue | |||
4. Later Stage VC (Series B) | 10-Feb-2022 | Completed | Generating Revenue | |||
3. Later Stage VC | 06-Aug-2021 | Completed | Generating Revenue | |||
2. Early Stage VC (Series A) | 09-Jun-2015 | $10M | $10M | Completed | Generating Revenue | |
1. Early Stage VC | 06-Mar-2014 | Completed | Generating Revenue |
Phagelux Patents
Phagelux Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3299459-B1 | Staphylococcus lyase and use thereof | Active | 18-May-2015 | ||
EP-3299459-A1 | Staphylococcus lyase and use thereof | Active | 18-May-2015 | ||
EP-3299459-A4 | Staphylococcus lyase and use thereof | Active | 18-May-2015 | ||
EP-3312275-A4 | Broad spectrum of streptococcus lyase and use thereof | Active | 13-Apr-2015 | ||
EP-3312275-B1 | Antibiotic chimeric lyase from streptococcus and uses thereof | Active | 13-Apr-2015 | C12N9/88 |
Phagelux Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Anhui Guokong Capital | Asset Manager | Minority | ||
BioSciKin | Corporation | Minority | ||
120 Capital | Venture Capital | Minority | ||
Moom Capital | Venture Capital | Minority | ||
Wuxi Capital | Government | Minority |
Phagelux Investments & Acquisitions (4)
Phagelux’s most recent deal was a Later Stage VC with NexaBiome for . The deal was made on 15-Mar-2021.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
NexaBiome | 15-Mar-2021 | Later Stage VC | Biotechnology | ||
Scithera Microbial Technologies | 14-Oct-2015 | Merger/Acquisition | Biotechnology | ||
OmniLytics (Multi-line Chemicals) | 20-Jul-2015 | Merger/Acquisition | Multi-line Chemicals | ||
Iveria Technologies (Novel Delivery Systems) | 23-Dec-2014 | Merger/Acquisition | Drug Delivery |
Phagelux Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
OmniLytics (Multi-line Chemicals) | Sandy, UT | 1954 |
Phagelux FAQs
-
When was Phagelux founded?
Phagelux was founded in 2014.
-
Where is Phagelux headquartered?
Phagelux is headquartered in Wuxi, China.
-
What industry is Phagelux in?
Phagelux’s primary industry is Drug Delivery.
-
Is Phagelux a private or public company?
Phagelux is a Private company.
-
What is Phagelux’s current revenue?
The current revenue for Phagelux is
. -
How much funding has Phagelux raised over time?
Phagelux has raised $10M.
-
Who are Phagelux’s investors?
Anhui Guokong Capital, BioSciKin, 120 Capital, Moom Capital, and Wuxi Capital are 5 of 8 investors who have invested in Phagelux.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »